#USA #Washington #Clinical Trials #Spectrum Science #Marie Emms

Spectrum Science Welcomes Marie Emms as President of Clinical Business

In an exciting development for the healthcare communications industry, Spectrum Science, an independent full-service strategic platform, has announced the appointment of Marie Emms as the new President of its Clinical Business. This strategic move marks a significant step toward enhancing clinical trial recruitment and retention services provided by Spectrum Science Clinical.

With an impressive career spanning over 30 years, Emms brings a wealth of knowledge and expertise in the healthcare communications field. Notably, she has dedicated 26 of those years specifically to clinical trials, collaborating with pharmaceutical and biotechnology companies across various therapeutic areas. Her experience covers every phase of the clinical trial journey, ensuring a comprehensive understanding of patient needs and regulatory requirements.

Amy Hutnik, President and Chief Commercial Officer at Spectrum Science, expressed great confidence in Emms’ capabilities, stating, "Marie’s background merges a profound understanding of the clinical trial ecosystem with remarkable communication skills that drive behavioral changes needed for success. Her insights into the pressures faced by biopharma companies today will be invaluable in helping them accelerate enrollment processes, thereby shortening clinical development timelines."

In her new role, Emms will oversee the development and execution of innovative patient engagement programs focused on improving trial enrollment and retention. Her strategy aims at aligning with the unique needs of each clinical protocol and patient population, reflecting Spectrum's commitment to personalized solutions. Emms is known for her collaborative approach, fostering partnerships across different functions to craft effective strategies in the complex landscape of clinical trials.

Emms expressed her enthusiasm about joining Spectrum, highlighting the company's pioneering history in trial acceleration. She noted, "The urgency for integration and a patient-centric approach has never been more critical. Spectrum’s extensive capabilities and AI-driven technology ecosystem are pivotal in generating significant momentum within the clinical space."

Before this role, Emms held senior positions at Johnson & Johnson and Bristol Myers Squibb, where she honed her strategic vision and operational insights from the sponsor's perspective. Furthermore, her tenure at Syneos Health, leading a patient engagement team, equipped her with valuable experience that will inform her leadership at Spectrum.

Emms also recently obtained a certification in AI in Pharma and Biotech from MIT Sloan, reinforcing Spectrum Science Clinical's dedication to innovation and data-driven strategies in patient engagement. The integration of her extensive knowledge will enhance Spectrum's MERIS™ platform, which is designed to streamline clinical trial enrollment and retention.

Following Emms’ arrival, Neil Weisman, the former President of Spectrum Science Clinical, transitions to Chief Development Officer. In this role, he will concentrate on cultivating enterprise-level partnerships that amplify strategic synergies across various therapeutic areas.

Spectrum Science continues to push the boundaries of healthcare communications, leveraging its award-winning model of integrated marketing and clinical trial services. With the strategic appointment of Marie Emms, the company is poised to further enhance its impact in health and life sciences, ensuring that they stay at the forefront of innovation in clinical trial processes. For more insights and updates on Spectrum Science, visit spectrumscience.com or follow on social media platforms including LinkedIn and Instagram.